靶向治疗联合新辅助放化疗在局部进展期直肠癌中的应用

国际肿瘤学杂志››2014,Vol. 41››Issue (2): 113-116.doi:10.3760/cma.j.issn.1673-422X.2014.02.011

靶向治疗联合新辅助放化疗在局部进展期直肠癌中的应用

周宁, 朱远, 罗加林

310022 杭州，浙江省肿瘤医院放疗科

收稿日期:2013-09-09修回日期:2013-12-02出版日期:2014-02-08发布日期:2014-01-26
通讯作者:朱远，E-mail: zhuyuan63@hotmail.com E-mail:zhuyuan63@hotmail.com

Targeted therapy combined with neoadjuvant chemoradiotherapy for locally advanced rectal cancer

Zhou Ning, Zhu Yuan, Luo Jialin

Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China

Received:2013-09-09Revised:2013-12-02Online:2014-02-08Published:2014-01-26
Contact:Zhu Yuan E-mail:zhuyuan63@hotmail.com

摘要/Abstract

摘要：目前新辅助放化疗联合全直肠系膜切除术（TME）是局部进展期直肠癌（LARC）的标准治疗模式。靶向药物在LARC新辅助治疗中耐受性及安全性良好，但与常规新辅助放化疗相比较，病理完全缓解（pCR）率并无提高，仍需大样本随机对照研究证实其在LARC新辅助治疗中的作用。

周宁, 朱远, 罗加林. 靶向治疗联合新辅助放化疗在局部进展期直肠癌中的应用[J]. 国际肿瘤学杂志, 2014, 41(2): 113-116.

Zhou Ning, Zhu Yuan, Luo Jialin. Targeted therapy combined with neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Journal of International Oncology, 2014, 41(2): 113-116.

［1］ Huerta S. New directions in the preoperative management of adenocarcinoma of the rectum［J］. Crit Rev Oncog, 2012, 17(4)：393-396. ［2］ Hong YS, Kim DY, Lim SB, et al. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: longterm results of a Phase Ⅱ study［J］. Int J Radiat Oncol Biol Phys, 2011, 79(4)：1171-1178. ［3］ Bertolini F, Chiara S, Bengala C, et al. Neoadjuvant treatment with singleagent cetuximab followed by 5FU, cetuximab, and pelvic radiotherapy: a phase Ⅱ study in locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2009, 73 (2)：466-472. ［4］ Velenik V, Ocvirk J, Oblak I, et al. A phase Ⅱ study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer［J］. Eur J Surg Oncol, 2010, 36(3)：244-250. ［5］ Sun PL, Li B, Ye QF. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase Ⅱ study［J］. Int J Colorectal Dis, 2012, 27(10)：1325-1332. ［6］ Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase Ⅱ clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with highrisk rectal cancer (EXPERTC)［J］. J Clin Oncol, 2012, 30(14)：1620-1627. ［7］ Kim SY, Hong YS, Kim DY, et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase Ⅱ study［J］. Int J Radiat Oncol Biol Phys, 2011, 81(3)：677-683. ［8］ Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX4 as firstline treatment for metastatic colorectal cancer: the OPUS study［J］. Ann Oncol, 2011, 22(7)：1535-1546. ［9］ Debucquoy A, Haustermans K, Daemen A, et al. Molecular response to cetuximab and efficacy of preoperative cetuximabbased chemoradiation in rectal cancer［J］. J Clin Oncol, 2009, 27(17)：2751-2757. ［10］ Erben P, Strbel P, Horisberger K, et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximabbased chemoradiotherapy in locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 81(4)：1032-1038. ［11］ Zhu Y, Liu LY, Luo JL, et al. Preoperative chemoradiation with nimotuzumab and capecitabine in patients with locally advanced rectal cancer: a phase Ⅱ study［J］. J Clin Oncol 30, 2012 (suppl: abstr e14049). ［12］ Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase Ⅰ trial results［J］. J Clin Oncol, 2006, 24(4)：656-662. ［13］ Valentini V, De Paoli A, Gambacorta MA, et al. Infusional 5fluorouracil and ZD1839 (GefitinibIressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase Ⅰ and Ⅱ Trial (1839IL/0092)［J］. Int J Radiat Oncol Biol Phys, 2008, 72(3)：644-649. ［14］田源, 蔡欣, 刘基巍. 结肠直肠癌的分子靶向治疗进展［J］. 癌症进展, 2010, 8(2)：151-155, 179. ［15］ Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase Ⅱ study［J］. J Clin Oncol, 2009, 27(18)：3020-3026. ［16］ Crane CH, Eng C, Feig BW, et al. Phase Ⅱ trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2010, 76(3)：824-830. ［17］ Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabinebased chemoradiotherapy in magnetic resonance imagingdefined poorprognosis locally advanced rectal cancer: the AVACROSS study［J］. Oncologist, 2011, 16(5)：614-620. ［18］ Velenik V, Ocvirk J, Music M, et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an openlabel phase Ⅱ study［J］. Radiat Oncol, 2011, 6：105. ［19］ Kennecke H, Berry S, Wong R, et al. Preoperative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase Ⅱ trial［J］. Eur J Cancer, 2012, 48(1)：37-45. ［20］ Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase Ⅱ trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecanrefractory colorectal cancer: the BOND2 study［J］. J Clin Oncol, 2007, 25(29)：4557-4561. ［21］ Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase Ⅲ study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in firstline advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity［J］. Ann Oncol, 2008, 19(4)：734-738. ［22］ Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase ⅢB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer［J］. J Clin Oncol, 2009, 27(5)：672680. ［23］ Wong NS, Fernando NH, Nixon AB ,et al. A phase Ⅱ study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer［J］. Anticancer Res, 2011, 31(1)：255-261.

[1]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[2]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[3]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[4]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[5]	王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[6]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[7]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安.新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[8]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英.HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[9]	黄辉, 丁江华.靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[10]	刘德宝, 孙子雯, 鲁守堂, 徐海东.ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[11]	王文德, 曾德.乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[12]	张丽, 向卓, 王强, 毕经旺.CAR-T免疫治疗相关的细胞因子释放综合征研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 377-381.
[13]	陈卓, 陶俊, 陈琳, 柯晶.外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[14]	徐放, 朱文钿.肝细胞癌合并微血管侵犯术后辅助治疗现状[J]. 国际肿瘤学杂志, 2023, 50(5): 304-309.
[15]	丁浩, 应劲涛, 付茂勇.CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.